FibroGen, Inc.

Contributing Author

Recent Articles by FibroGen, Inc.

Nov-10	FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update FGEN GlobeNewswire
Nov-03	FibroGen to Report Third Quarter 2025 Financial Results FGEN GlobeNewswire
Sep-24	FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer FGEN GlobeNewswire
Sep-02	FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million FGEN GlobeNewswire
Aug-27	FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference FGEN GlobeNewswire
Aug-18	FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation FGEN GlobeNewswire
Aug-11	FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update FGEN GlobeNewswire
Aug-07	FibroGen Announces Positive Type C Meeting with the FDA for Roxadustat in Patients with Anemia Associated with Lower-Risk Myelodysplastic Syndromes FGEN GlobeNewswire
Aug-04	FibroGen to Report Second Quarter 2025 Financial Results FGEN GlobeNewswire
Jun-12	FibroGen Announces 1-for-25 Reverse Stock Split FGEN GlobeNewswire
Jun-09	FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors FGEN GlobeNewswire
May-12	FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update FGEN GlobeNewswire
May-05	FibroGen to Report First Quarter 2025 Financial Results FGEN GlobeNewswire